Literature DB >> 19929575

Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients.

Katsunori Tatsugami1, Masatoshi Eto, Seiji Naito.   

Abstract

Interferon-alpha (IFN-alpha) has extremely broad effects on the immune system, and the influence of IFN-alpha on regulatory T (Treg) cells is not fully known. In this report, Treg cells were analyzed in patients with metastatic renal cell carcinoma (RCC) following IFN-alpha monotherapy or treatment with IFN-alpha and interleukin (IL)-2. CD4(+) and FoxP3(+) Treg cells were significantly decreased for 2 weeks after the initiation of IFN-alpha monotherapy, but recovered later as treatment proceeded. Patients treated with both IFN-alpha and IL-2 increased their Treg cell levels during the first 2 weeks after initiation of treatment. Patients who derived complete response (CR), partial response (PR), or stable disease (SD) from IFN-alpha monotherapy had lower Treg cell levels before treatment than did patients whose disease progressed. Low Treg cell levels before treatment may therefore be advantageous to subsequent immunotherapy with IFN-alpha, and predictive for treatment results in RCC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929575     DOI: 10.1089/jir.2009.0014

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.

Authors:  Anita Schwandt; Jorge A Garcia; Paul Elson; Jeanie Wyckhouse; James H Finke; Joanna Ireland; Pierre Triozzi; Ming Zhou; Robert Dreicer; Brian I Rini
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

2.  Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.

Authors:  Paolo A Ascierto; Maria Napolitano; Egidio Celentano; Ester Simeone; Giusy Gentilcore; Antonio Daponte; Mariaelena Capone; Corrado Caracò; Rosa Calemma; Gerardo Beneduce; Margherita Cerrone; Vincenzo De Rosa; Giuseppe Palmieri; Giuseppe Castello; John M Kirkwood; Francesco M Marincola; Nicola Mozzillo
Journal:  J Transl Med       Date:  2010-08-16       Impact factor: 5.531

3.  Immunotherapy for renal cell carcinoma.

Authors:  Momoe Itsumi; Katsunori Tatsugami
Journal:  Clin Dev Immunol       Date:  2011-01-03

4.  Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.

Authors:  Svetlana Karakhanova; Beate Mosl; Sabine Harig; Katharina von Ahn; Jasmin Fritz; Jan Schmidt; Dirk Jäger; Jens Werner; Alexandr V Bazhin
Journal:  Int J Mol Sci       Date:  2014-03-07       Impact factor: 5.923

5.  Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.

Authors:  Marina K Baine; Gabriela Turcu; Christopher R Zito; Adebowale J Adeniran; Robert L Camp; Lieping Chen; Harriet M Kluger; Lucia B Jilaveanu
Journal:  Oncotarget       Date:  2015-09-22

6.  Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy.

Authors:  Adrian Schwarzer; Benita Wolf; Jan L Fisher; Thomas Schwaab; Sven Olek; Udo Baron; Craig R Tomlinson; John D Seigne; Nancy A Crosby; Jiang Gui; Thomas H Hampton; Camilo E Fadul; John A Heaney; Marc S Ernstoff
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

Review 7.  Update on vaccine development for renal cell cancer.

Authors:  Nina Chi; Jodi K Maranchie; Leonard J Appleman; Walter J Storkus
Journal:  Open Access J Urol       Date:  2010-08-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.